|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolff I, May M, Hoschke B, Zigeuner R,
Cindolo L, Hutterer G, Schips L, De Cobelli O, Rocco B, De Nunzio
C, et al: Do we need new high-risk criteria for surgically treated
renal cancer patients to improve the outcome of future clinical
trials in the adjuvant setting? Results of a comprehensive analysis
based on the multicenter CORONA database. Eur J Surg Oncol.
42:744–750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello
G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E,
et al: Multilevel genomics-based taxonomy of renal cell carcinoma.
Cell Rep. 14:2476–2489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaelin WG Jr: The von Hippel-Lindau tumor
suppressor gene and kidney cancer. Clin Cancer Res. 10:6290S–5S.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iliopoulos O, Kibel A, Gray S and Kaelin
WG Jr: Tumour suppression by the human von Hippel-Lindau gene
product. Nat Med. 1:822–826. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanisawa K, Arai Y, Hirose N, Shimokata H,
Yamada Y, Kawai H, Kojima M, Obuchi S, Hirano H, Yoshida H, et al:
Exome-wide association study identifies CLEC3B missense variant
p.S106G as being associated with extreme longevity in east asian
populations. J Gerontol A Biol Sci Med Sci. 72:309–318.
2017.PubMed/NCBI
|
|
9
|
Clemmensen I, Petersen LC and Kluft C:
Purification and characterization of a novel, oligomeric,
plasminogen kringle 4 binding protein from human plasma:
Tetranectin. Eur J Biochem. 156:327–333. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wewer UM, Ibaraki K, Schjørring P, Durkin
ME, Young MF and Albrechtsen R: A potential role for tetranectin in
mineralization during osteogenesis. J Cell Biol. 127:1767–1775.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wewer UM, Iba K, Durkin ME, Nielsen FC,
Loechel F, Gilpin BJ, Kuang W, Engvall E and Albrechtsen R:
Tetranectin is a novel marker for myogenesis during embryonic
development, muscle regeneration, and muscle cell differentiation
in vitro. Dev Biol. 200:247–259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin X, Subramanian S, Hwang SJ, O'Donnell
CJ, Fox CS, Courchesne P, Muntendam P, Gordon N, Adourian A, Juhasz
P, et al: Protein biomarkers of new-onset cardiovascular disease:
Prospective study from the systems approach to biomarker research
in cardiovascular disease initiative. Arterioscler Thromb Vasc
Biol. 34:939–945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Han H, Yan X, Ding F, Su X, Wang
H, Chen Q, Lu L, Zhang R and Jin W: Tetranectin as a potential
biomarker for stable coronary artery disease. Sci Rep. 5:176322015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Z, Wang E, Hu R, Sun Y, Zhang L,
Jiang J, Zhang Y and Jiang H: Tetranectin gene deletion induces
Parkinson's disease by enhancing neuronal apoptosis. Biochem
Biophys Res Commun. 468:400–407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jensen BA and Clemmensen I: Plasma
tetranectin is reduced in cancer and related to metastasia. Cancer.
62:869–872. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nielsen H, Clemmensen I, Nielsen HJ and
Drivsholm A: Decreased tetranectin in multiple myeloma. Am J
Hematol. 33:142–144. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Høgdall CK, Høgdall EV, Hørding U,
Daugaard S, Clemmensen I, Nørgaard-Pedersen B and Toftager-Larsen
K: Plasma tetranectin and ovarian neoplasms. Gynecol Oncol.
43:103–107. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Høgdall CK, Christiansen M,
Nørgaard-Pedersen B, Bentzen SM, Kronborg O and Clemmensen I:
Plasma tetranectin and colorectal cancer. Eur J Cancer.
31A:888–894. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Felix K, Hauck O, Fritz S, Hinz U,
Schnölzer M, Kempf T, Warnken U, Michel A, Pawlita M and Werner J:
Serum protein signatures differentiating autoimmune pancreatitis
versus pancreatic cancer. PLoS One. 8:e827552013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lundstrøm MS, Høgdall CK, Nielsen AL and
Nyholm HC: Serum tetranectin and CA125 in endometrial
adenocarcinoma. Anticancer Res. 20:3903–3906. 2000.PubMed/NCBI
|
|
21
|
Arellano-Garcia ME, Li R, Liu X, Xie Y,
Yan X, Loo JA and Hu S: Identification of tetranectin as a
potential biomarker for metastatic oral cancer. Int J Mol Sci.
11:3106–3121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Høgdall CK, Hørding U, Nørgaard-Pedersen
B, Toftager-Larsen K and Clemmensen I: Serum tetranectin and CA-125
used to monitor the course of treatment in ovarian cancer patients.
Eur J Obstet Gynecol Reprod Biol. 57:175–178. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen H, Li H, Zhao J, Peng P, Shao M, Wu
H, Wang X, Chen L, Zhang Q, Ruan Y, et al: High intratumoral
expression of tetranectin associates with poor prognosis of
patients with gastric cancer after gastrectomy. J Cancer.
8:3623–3630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Obrist P, Spizzo G, Ensinger C, Fong D,
Brunhuber T, Schäfer G, Varga M, Margreiter R, Amberger A, Gastl G
and Christiansen M: Aberrant tetranectin expression in human breast
carcinomas as a predictor of survival. J Clin Pathol. 57:417–421.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heeran MC, Rask L, Høgdall CK, Kjaer SK,
Christensen L, Jensen A, Blaakaer J, Christensen Jarle IB and
Høgdall EV: Tetranectin positive expression in tumour tissue leads
to longer survival in Danish women with ovarian cancer. Results
from the ‘Malova’ ovarian cancer study. APMIS. 123:401–409. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mermel CH, Schumacher SE, Hill B, Meyerson
ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and
confident localization of the targets of focal somatic copy-number
alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: tool for the unification of biology. The Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang dW, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lam JS, Klatte T and Breda A: Staging of
renal cell carcinoma: Current concepts. Indian J Urol. 25:446–454.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moch H: The WHO/ISUP grading system for
renal carcinoma. Pathologe. 37:355–360. 2016.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz
KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et
al: Patterns of gene expression and copy-number alterations in
von-hippel lindau disease-associated and sporadic clear cell
carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Macé A, Kutalik Z and Valsesia A: Copy
number variation. Methods Mol Biol. 1793:231–258. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nickerson ML, Jaeger E, Shi Y, Durocher
JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko
V, et al: Improved identification of von Hippel-Lindau gene
alterations in clear cell renal tumors. Clin Cancer Res.
14:4726–4734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van Dam S, Võsa U, van der Graaf A, Franke
L and de Magalhães J: Gene co-expression analysis for functional
classification and gene-disease predictions. Brief Bioinform. 2017.
View Article : Google Scholar :
|
|
39
|
Cecchi F, Rabe DC and Bottaro DP:
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer.
46:1260–1270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Justilien V, Ali SA, Jamieson L, Yin N,
Cox AD, Der CJ, Murray NR and Fields AP: Ect2-dependent rRNA
synthesis is required for KRAS-TRP53-driven lung adenocarcinoma.
Cancer Cell. 31:256–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bracken AP, Pasini D, Capra M, Prosperini
E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway,
essential for proliferation and amplified in cancer. EMBO J.
22:5323–5335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ryu S and Driever W: Minichromosome
maintenance proteins as markers for proliferation zones during
embryogenesis. Cell Cycle. 5:1140–1142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi
X and Hoang BH: Frzb, a secreted Wnt antagonist, decreases growth
and invasiveness of fibrosarcoma cells associated with inhibition
of Met signaling. Cancer Res. 68:3350–3360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Andreeva AV and Kutuzov MA: Cadherin 13 in
cancer. Genes Chromosomes Cancer. 49:775–790. 2010.PubMed/NCBI
|
|
45
|
Liu X, Lan Y, Zhang D, Wang K, Wang Y and
Hua ZC: SPRY1 promotes the degradation of uPAR and inhibits
uPAR-mediated cell adhesion and proliferation. Am J Cancer Res.
4:683–697. 2014.PubMed/NCBI
|
|
46
|
Oh KY, Hong KO, Huh YS, Lee JI and Hong
SD: Decreased expression of SOX7 induces cell proliferation and
invasion and correlates with poor prognosis in oral squamous cell
carcinoma. J Oral Pathol Med. 46:752–758. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jafri M, Wake NC, Ascher DB, Pires DE,
Gentle D, Morris MR, Rattenberry E, Simpson MA, Trembath RC, Weber
A, et al: Germline Mutations in the CDKN2B tumor suppressor gene
predispose to renal cell carcinoma. Cancer Discov. 5:723–729. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Paz N, Levanon EY, Amariglio N, Heimberger
AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M,
Hirschberg A, et al: Altered adenosine-to-inosine RNA editing in
human cancer. Genome Res. 17:1586–1595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sánchez-Martín D, Otsuka A, Kabashima K,
Ha T, Wang D, Qian X, Lowy DR and Tosato G: Effects of DLC1
deficiency on endothelial cell contact growth inhibition and
angiosarcoma progression. J Natl Cancer Inst. 110:390–399. 2017.
View Article : Google Scholar :
|
|
50
|
Kim YM, Stone M, Hwang TH, Kim YG, Dunlevy
JR, Griffin TJ and Kim DH: SH3BP4 is a negative regulator of amino
acid-Rag GTPase-mTORC1 signaling. Mol Cell. 46:833–846. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shen YJ, Kong ZL, Wan FN, Wang HK, Bian
XJ, Gan HL, Wang CF and Ye DW: Downregulation of DAB2IP results in
cell proliferation and invasion and contributes to unfavorable
outcomes in bladder cancer. Cancer Sci. 105:704–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Høgdall CK, Christensen L and Clemmensen
I: The prognostic value of tetranectin immunoreactivity and plasma
tetranectin in patients with ovarian cancer. Cancer. 72:2415–2422.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Høgdall CK, Sölétormos G, Nielsen D,
Nørgaard-Pedersen B, Dombernowsky P and Clemmensen I: Prognostic
value of serum tetranectin in patients with metastatic breast
cancer. Acta Oncol. 32:631–636. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bamborough P, Chung CW, Demont EH, Furze
RC, Bannister AJ, Che KH, Diallo H, Douault C, Grandi P, Kouzarides
T, et al: A Chemical probe for the ATAD2 bromodomain. Angew Chem
Int Ed Engl. 55:11382–11386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Saha A, Kim Y, Gewirtz ADH, Jo B, Gao C
and McDowell IC: GTEx Consortium, Engelhardt BE and Battle A:
Co-expression networks reveal the tissue-specific regulation of
transcription and splicing. Genome Res. 27:1843–1858. 2017.
View Article : Google Scholar : PubMed/NCBI
|
